LIFECORE BIOMEDICAL INC (LFCR) Fundamental Analysis & Valuation

NASDAQ:LFCR • US5147661046

6.96 USD
-0.06 (-0.85%)
At close: Mar 6, 2026
7 USD
+0.04 (+0.57%)
After Hours: 3/6/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This LFCR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to LFCR. LFCR was compared to 57 industry peers in the Life Sciences Tools & Services industry. LFCR may be in some trouble as it scores bad on both profitability and health. LFCR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. LFCR Profitability Analysis

1.1 Basic Checks

  • In the past year LFCR has reported negative net income.
  • In the past year LFCR had a positive cash flow from operations.
  • LFCR had negative earnings in 4 of the past 5 years.
  • LFCR had negative operating cash flow in 4 of the past 5 years.
LFCR Yearly Net Income VS EBIT VS OCF VS FCFLFCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M

1.2 Ratios

  • With a Return On Assets value of -16.60%, LFCR is not doing good in the industry: 61.40% of the companies in the same industry are doing better.
  • Looking at the Return On Equity, with a value of -106.13%, LFCR is doing worse than 80.70% of the companies in the same industry.
Industry RankSector Rank
ROA -16.6%
ROE -106.13%
ROIC N/A
ROA(3y)-17.69%
ROA(5y)-20.17%
ROE(3y)-118.33%
ROE(5y)-99.51%
ROIC(3y)N/A
ROIC(5y)N/A
LFCR Yearly ROA, ROE, ROICLFCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200

1.3 Margins

  • The Gross Margin of LFCR (31.57%) is worse than 70.18% of its industry peers.
  • LFCR's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for LFCR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 31.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.85%
GM growth 5Y4.91%
LFCR Yearly Profit, Operating, Gross MarginsLFCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40 -60 -80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. LFCR Health Analysis

2.1 Basic Checks

  • LFCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, LFCR has more shares outstanding
  • Compared to 5 years ago, LFCR has more shares outstanding
  • Compared to 1 year ago, LFCR has a worse debt to assets ratio.
LFCR Yearly Shares OutstandingLFCR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
LFCR Yearly Total Debt VS Total AssetsLFCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • LFCR has an Altman-Z score of 0.31. This is a bad value and indicates that LFCR is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of 0.31, LFCR is not doing good in the industry: 61.40% of the companies in the same industry are doing better.
  • A Debt/Equity ratio of 3.67 is on the high side and indicates that LFCR has dependencies on debt financing.
  • LFCR has a worse Debt to Equity ratio (3.67) than 91.23% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.67
Debt/FCF N/A
Altman-Z 0.31
ROIC/WACCN/A
WACC9.47%
LFCR Yearly LT Debt VS Equity VS FCFLFCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M

2.3 Liquidity

  • A Current Ratio of 2.80 indicates that LFCR has no problem at all paying its short term obligations.
  • LFCR has a Current ratio (2.80) which is in line with its industry peers.
  • A Quick Ratio of 1.67 indicates that LFCR should not have too much problems paying its short term obligations.
  • LFCR has a Quick ratio of 1.67. This is comparable to the rest of the industry: LFCR outperforms 42.11% of its industry peers.
Industry RankSector Rank
Current Ratio 2.8
Quick Ratio 1.67
LFCR Yearly Current Assets VS Current LiabilitesLFCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. LFCR Growth Analysis

3.1 Past

  • The earnings per share for LFCR have decreased strongly by -2114.69% in the last year.
  • Looking at the last year, LFCR shows a small growth in Revenue. The Revenue has grown by 5.31% in the last year.
  • LFCR shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.25% yearly.
EPS 1Y (TTM)-2114.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.82%
Revenue 1Y (TTM)5.31%
Revenue growth 3Y-11.48%
Revenue growth 5Y-4.25%
Sales Q2Q%25.93%

3.2 Future

  • The Earnings Per Share is expected to grow by 23.41% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, LFCR will show a very strong growth in Revenue. The Revenue will grow by 21.24% on average per year.
EPS Next Y36.35%
EPS Next 2Y22.31%
EPS Next 3Y23.41%
EPS Next 5YN/A
Revenue Next Year1.62%
Revenue Next 2Y6.45%
Revenue Next 3Y8.7%
Revenue Next 5Y21.24%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LFCR Yearly Revenue VS EstimatesLFCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
LFCR Yearly EPS VS EstimatesLFCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. LFCR Valuation Analysis

4.1 Price/Earnings Ratio

  • LFCR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LFCR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LFCR Price Earnings VS Forward Price EarningsLFCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

  • LFCR's Enterprise Value to EBITDA ratio is in line with the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 67.89
LFCR Per share dataLFCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as LFCR's earnings are expected to grow with 23.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.31%
EPS Next 3Y23.41%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LFCR Dividend Analysis

5.1 Amount

  • LFCR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LFCR Fundamentals: All Metrics, Ratios and Statistics

LIFECORE BIOMEDICAL INC

NASDAQ:LFCR (3/6/2026, 8:00:02 PM)

After market: 7 +0.04 (+0.57%)

6.96

-0.06 (-0.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)01-02
Earnings (Next)04-01
Inst Owners76.18%
Inst Owner ChangeN/A
Ins Owners1.78%
Ins Owner Change-0.51%
Market Cap260.79M
Revenue(TTM)135.27M
Net Income(TTM)-39.04M
Analysts78.18
Price Target8.93 (28.3%)
Short Float %7.45%
Short Ratio19.25
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)15.4%
Min EPS beat(2)-7.29%
Max EPS beat(2)38.08%
EPS beat(4)2
Avg EPS beat(4)-40.23%
Min EPS beat(4)-207.19%
Max EPS beat(4)38.08%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.4%
Min Revenue beat(2)1.03%
Max Revenue beat(2)5.77%
Revenue beat(4)4
Avg Revenue beat(4)4.46%
Min Revenue beat(4)1.03%
Max Revenue beat(4)7.32%
Revenue beat(8)6
Avg Revenue beat(8)3.19%
Revenue beat(12)7
Avg Revenue beat(12)-4.87%
Revenue beat(16)8
Avg Revenue beat(16)-9.71%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-7.04%
EPS NY rev (1m)0%
EPS NY rev (3m)-9.06%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.74%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.84%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.93
P/FCF N/A
P/OCF 118.6
P/B 7.09
P/tB 13.94
EV/EBITDA 67.89
EPS(TTM)-1.07
EYN/A
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)0.06
OCFY0.84%
SpS3.61
BVpS0.98
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -16.6%
ROE -106.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 31.57%
FCFM N/A
ROA(3y)-17.69%
ROA(5y)-20.17%
ROE(3y)-118.33%
ROE(5y)-99.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.85%
GM growth 5Y4.91%
F-Score4
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 3.67
Debt/FCF N/A
Debt/EBITDA 24.11
Cap/Depr 146.73%
Cap/Sales 8.69%
Interest Coverage N/A
Cash Conversion 39.27%
Profit Quality N/A
Current Ratio 2.8
Quick Ratio 1.67
Altman-Z 0.31
F-Score4
WACC9.47%
ROIC/WACCN/A
Cap/Depr(3y)177.04%
Cap/Depr(5y)161.61%
Cap/Sales(3y)15.06%
Cap/Sales(5y)14.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2114.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.82%
EPS Next Y36.35%
EPS Next 2Y22.31%
EPS Next 3Y23.41%
EPS Next 5YN/A
Revenue 1Y (TTM)5.31%
Revenue growth 3Y-11.48%
Revenue growth 5Y-4.25%
Sales Q2Q%25.93%
Revenue Next Year1.62%
Revenue Next 2Y6.45%
Revenue Next 3Y8.7%
Revenue Next 5Y21.24%
EBIT growth 1Y60.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year688.24%
EBIT Next 3Y120.25%
EBIT Next 5YN/A
FCF growth 1Y80.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y109.07%
OCF growth 3YN/A
OCF growth 5YN/A

LIFECORE BIOMEDICAL INC / LFCR FAQ

What is the fundamental rating for LFCR stock?

ChartMill assigns a fundamental rating of 2 / 10 to LFCR.


Can you provide the valuation status for LIFECORE BIOMEDICAL INC?

ChartMill assigns a valuation rating of 1 / 10 to LIFECORE BIOMEDICAL INC (LFCR). This can be considered as Overvalued.


Can you provide the profitability details for LIFECORE BIOMEDICAL INC?

LIFECORE BIOMEDICAL INC (LFCR) has a profitability rating of 1 / 10.


Can you provide the financial health for LFCR stock?

The financial health rating of LIFECORE BIOMEDICAL INC (LFCR) is 2 / 10.